Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The CREDENCE clinical trial evaluated the effects of canagliflozin 100 mg daily versus placebo in 4401 patients with T2DM and chronic kidney disease (CKD)
Suspected adverse reactions should be reported via the MHRA Yellow Card Scheme
The clinical trial data is specifically reassuring on this point: across six trials involving approximately 900 participants, glucose levels, insulin levels, and markers of insulin sensitivity remained unchanged from baseline
rapid degradation limits systemic exposure
Palmero S, Bottazzi C, Costa M, Leone M, Fugassa E
Would you prefer a weekly injection
US$ 26.31
US$ 22.58
US$ 25.29
US$ 24.18
US$ 25.58
US$ 24.40
US$ 28.66
US$ 22.94
US$ 22.82
